Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
immunology and microbiology
Short communication: High rates of thymidine analogue mutations and dual-class resistance among HIV-infected Ugandan children failing first-line antiretroviral therapy
AIDS Research and Human Retroviruses, Volume 29, No. 6, Year 2013
Notification
URL copied to clipboard!
Description
HIV-infected children are at high risk of acquiring drug-resistant viruses, which is of particular concern in settings where antiretroviral drug options are limited. We aimed to assess resistance patterns and predict viral drug susceptibility among children with first-line antiretroviral therapy (ART) failure in Uganda. A cross-sectional analysis of children switching ART regimens due to first-line failure was performed at three clinical sites in Uganda. HIV-RNA determination and genotypic resistance testing on all specimens with HIV-RNA >1,000 copies/ml were performed. Major drug resistance mutations were scored using the 2011 International Antiviral Society-USA list. The Stanford algorithm was used to predict drug susceptibility. At the time of switch, 44 genotypic resistance tests were available for 50 children. All children harbored virus with nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance [95% confidence interval (CI) 92-100%] and NRTI resistance was present in 98% (95% CI 88-100%). Forty-six percent (95% CI 30-61%) of children harbored ≥2 thymidine analog mutations. M184V was identified as the only NRTI mutation in 27% (95% CI 15-43%). HIV susceptibility to NRTIs, with the exception of tenofovir, was reduced in ≥60% of children. Ugandan children experiencing first-line ART failure in our study harbored high rates of dual-class and accumulated HIV drug resistance. Methods to prevent treatment failure, including adequate pediatric formulations and alternative second-line treatment options, are urgently needed. © Mary Ann Liebert, Inc.
Authors & Co-Authors
Sigaloff, Kim Catherina Eve
Netherlands, Amsterdam
Pharmaccess Foundation
Netherlands, Amsterdam
Amsterdam Umc - University of Amsterdam
Kayiwa, Joshua
Uganda, Kampala
Joint Clinical Research Center Uganda
Musiime, Victor
Uganda, Kampala
Joint Clinical Research Center Uganda
Calis, Job C.J.
Netherlands, Amsterdam
Emma Kinderziekenhuis
Kaudha, Elizabeth
Uganda, Kampala
Joint Clinical Research Center Uganda
Mukuye, Andrew
Uganda, Gulu
Joint Clinical Research Centre
Matama, Christine
Uganda, Gulu
Joint Clinical Research Centre
Nankya, Immaculate L.
Uganda, Kampala
Joint Clinical Research Center Uganda
Nakatudde-Katumba, Lillian
Uganda, Kampala
Joint Clinical Research Center Uganda
Dekker, John T.
Netherlands, Amsterdam
Pharmaccess Foundation
Hamers, Raph L.
Netherlands, Amsterdam
Pharmaccess Foundation
Netherlands, Amsterdam
Amsterdam Umc - University of Amsterdam
Mugyenyi, Peter N.
Uganda, Kampala
Joint Clinical Research Center Uganda
Rinke de Wit, Tobias Floris
Netherlands, Amsterdam
Pharmaccess Foundation
Netherlands, Amsterdam
Amsterdam Umc - University of Amsterdam
Kityo, Cissy Mutuluuza
Uganda, Kampala
Joint Clinical Research Center Uganda
Statistics
Citations: 19
Authors: 14
Affiliations: 5
Identifiers
Doi:
10.1089/aid.2012.0218
ISSN:
08892229
e-ISSN:
19318405
Research Areas
Cancer
Infectious Diseases
Maternal And Child Health
Study Design
Cross Sectional Study
Study Locations
Uganda